Market Cap | 358.10B | P/E | 39.00 | EPS this Y | 28.90% | Ern Qtrly Grth | 3.20% |
Income | 89.9B | Forward P/E | 28.02 | EPS next Y | 24.80% | 50D Avg Chg | -1.00% |
Sales | 258B | PEG | 82.80 | EPS past 5Y | 21.10% | 200D Avg Chg | 10.00% |
Dividend | N/A | Price/Book | 35.68 | EPS next 5Y | 2.80% | 52W High Chg | -8.00% |
Recommedations | 2.20 | Quick Ratio | 0.74 | Shares Outstanding | 3.38B | 52W Low Chg | 67.00% |
Insider Own | 0.00% | ROA | 22.80% | Shares Float | 3.18B | Beta | 0.15 |
Inst Own | 10.21% | ROE | 88.57% | Shares Shorted/Prior | 5.80M/5.27M | Price | 158.34 |
Gross Margin | 84.53% | Profit Margin | 34.84% | Avg. Volume | 1,289,590 | Target Price | 149.71 |
Oper. Margin | 46.48% | Earnings Date | Nov 6 | Volume | 832,759 | Change | -2.10% |
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.